SangJoon Lee

7PUBLICATIONS
42CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Models of care and place of birthApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Epidemiological modellingToxicology (incl. clinical toxicology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Apr 17, 2025
Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn's disease and ulcerative colitis: 2-year results from open-label extensions of two randomized controlled trials (LIBERTY).

Jean-Frederic Colombel, William J Sandborn, Stefan Schreiber

|Mar 07, 2023
Six-Year Survival Outcomes for Patients with HER2-Positive Early Breast Cancer Treated with CT-P6 or Reference Trastuzumab: Observational Follow-Up Study of a Phase 3 Randomised Controlled Trial.

Justin Stebbing, Yauheni Baranau, Valery Baryash

|Sep 03, 2021
Long-term efficacy and safety of CT-P10 or rituximab in untreated advanced follicular lymphoma: a randomized phase 3 study.

Christian Buske, Wojciech Jurczak, Juan-Manuel Sancho

|Jun 20, 2021
Long-term efficacy and safety of CT-P6 versus trastuzumab in patients with HER2-positive early breast cancer: final results from a randomized phase III trial.

Justin Stebbing, Yauheni V Baranau, Valery Baryash

|Apr 06, 2021
Randomised, phase I pharmacokinetic study of adalimumab biosimilar CT-P17 (40 mg/0.4 mL) by autoinjector and prefilled syringe in healthy subjects.

Antonia Davidson, Darin Brimhall, Jonathan Kay

|May 02, 2020
Post-Marketing Pooled Safety Analysis for CT-P13 Treatment of Patients with Immune-Mediated Inflammatory Diseases in Observational Cohort Studies.

Sang Joon Lee, KyungMin Baek, Sujin Lee

Pageof 2

Frequent Collaborators

1 joint publications

KyungMin Baek

1 joint publications

Yoon Jee Lee

1 joint publications

Jeong Eun Park

1 joint publications

Daniel E Furst